Filing Details
- Accession Number:
- 0001209191-19-044607
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-08-05 16:59:21
- Reporting Period:
- 2019-08-01
- Accepted Time:
- 2019-08-05 16:59:21
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1492426 | Horizon Therapeutics Public Ltd Co | HZNP | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1769107 | Jeff Kent | C/O Horizon Therapeutics Plc Connaught House, 1St Fl, 1 Burlington Rd Dublin L2 4 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2019-08-01 | 20,000 | $0.00 | 127,115 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2019-08-01 | 8,860 | $24.97 | 118,255 | No | 4 | F | Direct | |
| Ordinary Shares | Disposition | 2019-08-05 | 11,140 | $23.84 | 107,115 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Restricted Stock Units | Disposition | 2019-08-01 | 20,000 | $0.00 | 20,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 23, 2019.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.33 to $23.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- On August 1, 2017, the reporting person was granted 40,000 restricted stock units, vesting in two equal annual installments beginning on the first anniversary of the grant date.
Billionaire Hedge Funds
